Proteonomix, Inc. , a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of…
The rodent recovery spurs hope that humans could one day benefit from similar treatments. Rats once paralyzed from complete surgical cuts through their spinal cords can walk again after stem cells were transplanted into the site of the injury, report r…
Proteonomix, Inc. , a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-s…
SEATTLE, Sept. 11, 2012 /PRNewswire/ — Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation …
Lake County-based drugmakers Abbott Laboratories and Astellas Pharma said they will collaborate on a clinical trial on a vaccine licensed from Vical Inc. for preventing
Abbott To Collaborate With Astellas Pharma In Phase 3 Trial For ASP0113
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.
Alnylam Pharma Reveal Phase IIb Trial With ALN-RSV01 Missed Primary Endpoint
PRINCETON, N.J., Sept. 4, 2012 /PRNewswire/ — Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute …
StemCells Announces Positive Interim Data From Spinal Cord Injury Trial